Patient implants in Parkinsons trial completed

Living Cell Technologies Limited today announced that the final patient has been successfully implanted in its Phase I/IIa clinical trial of regenerative cell therapy NTCELL for Parkinsons disease. The operation took place at Auckland City Hospital last week.

The Phase I/IIa clinical trial, led by Dr Barry Snow, is an open-label investigation of the safety and clinical effects of NTCELL in patients who no longer respond to current therapy. Dr Snow MBChB, FRACP, FRCPC, leads the Auckland Movement Disorders Clinic at the Auckland District Health Board and is an internationally recognised clinician and researcher in Parkinsons disease.

LCT anticipates presenting the results of the 26-week trial at the 19th International Congress of Parkinsons Disease and Movement Disorders in San Diego in June 2015.

Dr Ken Taylor, chief executive, notes that the success of the implant procedure means that LCTs clinical programme remains on track.

"The treatment phase of the trial has been completed on schedule. We believe NTCELL has the potential to be the first disease-modifying treatment for patients who are failing the current conventional treatment for Parkinsons disease," said Dr Taylor.

Read more:
Patient implants in Parkinsons trial completed